Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Enzyme-Linked Immunosorbent Assay

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Simultaneous Nucleation-Nanowelding Generates Uniform Plasmonic Au-Au Nanojunctions in 3D-Welded Gold Nanostructures.

Small (Weinheim an der Bergstrasse, Germany)·2026

Same author

Wide excision with clitovulvopexy for the treatment of chronic vulvar pruritus: A new surgical technique.

Taiwanese journal of obstetrics & gynecology·2026

Same author

Robust SERS Platform Enabled by Silver-Nanoparticle-Loaded Hydrogel Millibeads for Trace Detection in High-Salt and Protein-Rich Complex Matrixes.

Nano letters·2026

Same author

Electrophoresis-assisted SERS-LFA strip for simultaneous HIV and HBV detection.

Biosensors & bioelectronics·2026

Same author

Advances in intelligent multi-mode lateral flow assays: from multi-metallic nanomaterials to smart analytical integration.

Chemical Society reviews·2026

Same author

Vertically Stacked Paper-Based Microarray Device for High-Throughput SERS Detection of Two Cancer Biomarkers.

Small (Weinheim an der Bergstrasse, Germany)·2026

Same journal

Tunable self-assembling cellular microarray for single-neutrophil vital and suicidal extracellular traps.

Lab on a chip·2026

Same journal

Precise programmable tumor cell subpopulation sorting <i>via</i> an electromagnetic microfluidic platform.

Lab on a chip·2026

Same journal

Bridging dimensions: combining one- and two-photon 3D printing for microfluidic device fabrication.

Lab on a chip·2026

Same journal

Microfluidic rare cell analysis beyond counting: workflow design from enrichment to multi-omics.

Lab on a chip·2026

Same journal

A sperm racetrack to separate sperm by swim speed.

Lab on a chip·2026

Same journal

Controlled encapsulation and droplet size prediction in two-step microfluidic double emulsions.

Lab on a chip·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 20, 2026

Computer Numerical Control Micromilling of a Microfluidic Acrylic Device with a Staggered Restriction for Magnetic Nanoparticle-Based Immunoassays

Computer Numerical Control Micromilling of a Microfluidic Acrylic Device with a Staggered Restriction for Magnetic Nanoparticle-Based Immunoassays

Published on: June 23, 2022

SERS-based immunoassay using a gold array-embedded gradient microfluidic chip.

Moonkwon Lee¹, Kangsun Lee, Ki Hyung Kim

¹Department of Bionano Engineering, Hanyang University, Ansan 426-791, South Korea.

|July 17, 2012

Summary

This summary is machine-generated.

A new automated microfluidic chip uses gold nanospheres for rapid and sensitive surface-enhanced Raman scattering (SERS) immunoassays. This technology enables fast, accurate detection of cancer biomarkers like alpha-fetoprotein (AFP).

More Related Videos

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets

Published on: March 17, 2023

Rapid Nanoprobe Signal Enhancement by In Situ Gold Nanoparticle Synthesis

Rapid Nanoprobe Signal Enhancement by In Situ Gold Nanoparticle Synthesis

Published on: March 7, 2018

Related Experiment Videos

Last Updated: May 20, 2026

Computer Numerical Control Micromilling of a Microfluidic Acrylic Device with a Staggered Restriction for Magnetic Nanoparticle-Based Immunoassays

Computer Numerical Control Micromilling of a Microfluidic Acrylic Device with a Staggered Restriction for Magnetic Nanoparticle-Based Immunoassays

Published on: June 23, 2022

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets

Published on: March 17, 2023

Rapid Nanoprobe Signal Enhancement by In Situ Gold Nanoparticle Synthesis

Rapid Nanoprobe Signal Enhancement by In Situ Gold Nanoparticle Synthesis

Published on: March 7, 2018

Area of Science:

Biomedical Engineering
Nanotechnology
Analytical Chemistry

Background:

Surface-enhanced Raman scattering (SERS) offers high sensitivity for biomarker detection.
Traditional immunoassays can be time-consuming and prone to inaccuracies.
Microfluidic devices enable precise control over biological assays.

Purpose of the Study:

To develop a programmable, automated microfluidic chip for SERS-based immunoassays.
To integrate gradient microfluidics with gold microarray wells for enhanced detection.
To create a convenient and reproducible platform for cancer biomarker analysis.

Main Methods:

Development of a microfluidic chip with gold-patterned microarray wells.
Utilizing hollow gold nanospheres (HGNs) as SERS agents.
Automated generation of biomarker concentration gradients using microfluidic gradient generators.
Quantitative immunoassay of alpha-fetoprotein (AFP) as a model.

Main Results:

The platform demonstrated sensitive and reproducible SERS-based immunoassay capabilities.
Automated gradient generation eliminated manual dilution, improving accuracy.
The entire assay process, from dilution to detection, was completed in under 60 minutes.
Successful quantitative immunoassay of AFP was achieved.

Conclusions:

The developed SERS-based microfluidic assay is a powerful tool for rapid cancer biomarker detection.
Automation and microfluidic gradient generation enhance assay convenience and reproducibility.
This novel technique offers significant advantages over existing SERS immunoassay methods for clinical applications.